Business Wire

CA-LEGENDARY-ENTERTAIN

18.7.2022 17:02:12 CEST | Business Wire | Press release

Share
Warner Bros. Pictures and Legendary Pictures Return to Arrakis for Denis Villeneuve’s “Dune: Part Two”

Coming off the heels of the critical and box-office success of the six-time Academy Award® winning first film, Warner Bros. Pictures and Legendary Entertainment have begun production on the highly-anticipated follow-up, “Dune: Part Two,” once again directed by Oscar nominee Denis Villeneuve (“Dune: Part One,” “Arrival,” “Blade Runner 2049”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005284/en/

The big-screen epic continues the adaptation of Frank Herbert’s acclaimed bestseller DUNE with returning stars including: Oscar nominee Timothée Chalamet (“Wonka,” “Call Me by Your Name”), Zendaya (“Spider-Man: No Way Home,” “Malcolm & Marie,” “Euphoria”), Rebecca Ferguson (“Mission: Impossible – Dead Reckoning”), Oscar winner Javier Bardem (“No Country for Old Men,” “Being the Ricardos”), Oscar nominee Josh Brolin (“Glass Onion: A Knives Out Mystery,” “Army of the Dead”), Stellan Skarsgård (the “Mamma Mia!” films, “Avengers: Age of Ultron”), Dave Bautista (the “Guardians of the Galaxy” films, “Thor: Love and Thunder”), Oscar nominee Charlotte Rampling (“45 Years,” “Assassin’s Creed”), and Stephen McKinley Henderson (“Fences,” “Lady Bird”). Also joining the returning cast are Austin Butler (“Elvis,” “Once Upon A Time…In Hollywood”) as the notorious Feyd Rautha and screen legend Christopher Walken (“The Deer Hunter,” “Hairspray”) as the Emperor. Florence Pugh (“Black Widow,” “Little Women”), Léa Seydoux (the “James Bond” franchise and “Crimes of the Future”), and Souheila Yacoub (the “No Man’s Land” series, “Climax”) round out the extensive ensemble cast.

This follow-up film will explore the mythic journey of Paul Atreides as he unites with Chani and the Fremen while on a warpath of revenge against the conspirators who destroyed his family. Facing a choice between the love of his life and the fate of the known universe, he endeavors to prevent a terrible future only he can foresee.

Villeneuve is directing “Dune: Part Two” from a screenplay he co-wrote with Jon Spaihts based on Herbert’s novel. The film is being produced by Denis Villeneuve, Mary Parent, Cale Boyter, Tanya Lapointe and Patrick McCormick. The executive producers are Josh Grode, Herbert W. Gains, Brian Herbert, Byron Merritt, Kim Herbert, Thomas Tull, Jon Spaihts, Richard P. Rubinstein and John Harrison, with Kevin J. Anderson serving as creative consultant.

Once again, Villeneuve is collaborating with Oscar-winning director of photography Greig Fraser (“Lion,” “Zero Dark Thirty,” “Rogue One: A Star Wars Story”), three-time Oscar-nominated costume designer Jacqueline West (“The Revenant,” “The Curious Case of Benjamin Button,” “Quills”), and Oscar-nominated makeup, hair and prosthetic designer Donald Mowat (“Blade Runner 2049”). Multiple Oscar-winning composer Hans Zimmer (“Blade Runner 2049,” “Inception,” “Gladiator,” “The Lion King”) is again on hand to create the score. Villeneuve is also reteaming with Oscar-winning production designer Patrice Vermette (“Arrival,” “Sicario,” “The Young Victoria”), Oscar-winning editor Joe Walker (“Blade Runner 2049,” “Arrival,” “12 Years a Slave”), three-time Oscar-winning visual effects supervisor Paul Lambert (“First Man,” “Blade Runner 2049”), and Oscar-winning special effects supervisor Gerd Nefzer (“Blade Runner 2049”).

“Dune” is being filmed on location in Budapest, Abu Dhabi, Jordan and Italy. The film is slated for a November 17, 2023 worldwide release from Warner Bros. Pictures and Legendary Entertainment.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye